Lisa and Nicky Holdeman are ensuring a bright future of UH med students. Photo courtesy of University of Houston

University of Houston medical students and staff will receive a gift that's just what the doctor ordered.

A prestigious and longtime UH power couple has bequeathed two major gifts a major gift to the school's burgeoning College of Medicine. Dr. Nicky and Lisa Holdeman — who together boast more than 45 years at the university — have established an endowed and chair/professorship and a scholarship for medical students, the school announced.

In their will/trust the Holdemans have established, per UH:

  • The Nicky R. and Lisa K. Holdeman Endowed Professorship/Chair, which will support a clinical teaching faculty member responsible for the oversight and strategic direction of the College of Medicine's clinics, as well as enhancing the student and patient experience.
  • The Nicky R. and Lisa K. Holdeman Endowed Scholarship, which will support students in the College of Medicine, which was founded in 2020 on a social mission to improve health and health care in underserved communities in Houston and across Texas.

The Holdemans say that they were inspired by the UH College of Medicine's mission to address a significant statewide primary care physician shortage and how social determinants of health, such as income, housing, food supply and transportation, contribute to health outcomes.

"I have a true admiration for the comprehensive physician, someone comfortable addressing multiple health issues," Nicky Holdeman relays in a statement. "The physicians being trained at the University of Houston will be well prepared to manage most of the patients, with most conditions, most of the time. That's really what primary care medicine is all about."

As previously reported, UH's medical school will welcome its second class of 30 students this summer and will have 480 students at full enrollment, within the decade.

More on the duo, who have been married for 38 years: A UH biography notes that Nicky, physician and professor emeritus at the UH College of Optometry, served as associate dean for clinical education and executive director of the University Eye Institute during his 30 years at the college. He retired in 2019.

Meanwhile, Lisa joined UH in 2006 and serves as vice chancellor for the UH System and vice president for UH marketing and communications. She works directly with UH System Chancellor and UH President Renu Khator and school leadership.

"This gift is especially gratifying because it comes from two dedicated UH leaders whose professional careers have already contributed so much to our University's success," said Renu Khator. "That kind of enlightened commitment on their part sets an admirable example. I know I speak for many when I express our deep appreciation for their generous support of the College of Medicine and the important work it is undertaking in our community."

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston brain health co. secures $6.5M for rare disease study

neuro funding

Houston-based Goldenrod Therapeutics, part of Fannin Partners' portfolio, has announced the initial close of a $6.5 million series seed preferred stock round.

The round was led by Ataxia Ventures and an affiliate of Fannin, according to a news release.

Goldenrod Therapeutics plans to use the funding to support manufacturing, formulation optimization, IND-enabling studies and a Phase I study of its drug to treat brain inflammation, known as 11h.

The study will consider how 11h, which blocks the enzyme PDE4, could treat Friedreich’s ataxia (FA), a rare genetic disease that affects movement, speech and balance. To date, other PDE4 inhibitors have proven to regulate neuroinflammation and neuronal signaling, but have had adverse gastrointestinal side effects or have not reached enough of the central nervous system, according to Goldenrod.

The company says its 11h is expected to have "broad applicability" with limited emetric side effects.

“Our 11h program is a next-generation, orally bioavailable, brain-penetrant PDE4 inhibitor, where researchers overcame longstanding limitations associated with earlier PDE4 inhibitors," Dr. Dev Chatterjee, CEO of Goldenrod, said in the news release. "We believe this creates the potential for a best-in-class therapy for Friedreich’s Ataxia and a potential foundation for development across multiple neurodegenerative and neuroinflammatory disorders.”

11h was first developed at the University of Nebraska Medical Center (UNeMed). Houston-based Fannin Partners in-licensed the product 2020 and landed SBIR Phase I funding to support its initial development for opioid use disorder soon after.

Goldenrod has also received funding to study 11h's effectiveness for multiple sclerosis, methamphetamine addiction and cocaine addiction.

Goldenrod says it is developing 11h to target a variety of neurological and inflammatory conditions, including Alzheimer's disease, multiple sclerosis, ALS, substance use disorders, Batten disease, pain and traumatic brain injury.

27 Houston companies make Fortune 500 for 2026, led by energy giants

Houston HQs

Editor's note: This article has been updated to correct the number of companies based in the Dallas-Fort Worth area.

Houston is a giant among U.S. hubs for corporate headquarters.

The 2026 Fortune 500 lists 27 companies based in the Houston area, with many energy companies claiming top spots. Houston ties with Chicago for the second-most Fortune 500 headquarters, preceded only by New York City (53). Dallas-Fort Worth is home to 24 Fortune 500 headquarters.

Texas leads the nation for Fortune 500 headquarters (57), with California in the No. 2 spot and New York at No. 3.

“Texas is the undisputed headquarters of headquarters,” Gov. Greg Abbott said in a news release. “The world’s leading businesses invest with confidence in Texas because of our welcoming business climate, predictable regulatory environment, and skilled and growing workforce. People and businesses are choosing Texas because Texas works.”

The 2026 Fortune 500 ranks the largest U.S. corporations based on revenue in fiscal year 2025.

Here’s a rundown of the 27 Fortune 500 companies based in the Houston area.

  • No. 9 ExxonMobil
  • No. 21 Chevron
  • No. 29 Phillips 66
  • No.55 Sysco
  • No. 75 ConocoPhillips
  • No. 89 Enterprise Products Partners
  • No. 103 Plains GP Holdings
  • No. 133 Hewlett Packard Enterprise
  • No. 149 NRG Energy
  • No. 157 Quanta Services
  • No. 164 Baker Hughes
  • No. 173 Occidental Petroleum
  • No. 179 Waste Management
  • No. 201 EOG Resources
  • No. 204 Group 1 Automotive
  • No. 207 Halliburton
  • No. 223 Cheniere Energy
  • No. 236 Corebridge Financial
  • No. 262 Targa Resources
  • No. 266 Kinder Morgan
  • No. 388 Westlake
  • No. 435 CenterPoint Energy
  • No. 438 APA
  • No. 440 Comfort Systems USA
  • No. 455 NOV
  • No. 488 KBR
  • No. 496 Coterra Energy. Oklahoma City, Oklahoma-based Devon Energy and Houston-based Coterra Energy merged in early May, with the combined company retaining the Devon Energy name and the Houston headquarters.

The Greater Houston Partnership notes the Houston area soon will welcome its 28th Fortune 500 company. Expand Energy (formerly Chesapeake Energy), appearing at No. 362 on the 2026 list, says it’s moving its headquarters from Oklahoma City to Spring this year.

As the natural gas producer prepares to relocate to Texas, it’s hunting for a new leader. Nick Dell’Osso stepped down as president and CEO earlier this year. Board Chairman Michael Wichterich is interim president and CEO.

Dell’Osso became president and CEO of Oklahoma City-based Gulfport Energy effective May 28.

---

This article first appeared on EnergyCapitalHTX.com.